Blocking immune ‘signal two’ expands gut tolerance cells, may open new IBD treatments Inflammatory bowel disease (IBD) affects millions worldwide, causing chronic inflammation in the digestive tract that can lead to debilitating symptoms and reduced quality of life. While current treatments focus on suppressing inflammation, recent research points to a more promising approach: enhancing the body’s natural ability to tolerate gut microbes and food proteins. A study published April 24, 2026, in the Journal of Experimental Medicine by investigators at Weill Cornell Medicine has uncovered an unexpected mechanism for promoting immune tolerance in the intestine. The research reveals that blocking a specific cell-to-cell signal—previously thought necessary for expanding tolerance-enforcing immune cells—actually drives tolerance through a distinct subset of cells and powerfully suppresses gut inflammation in preclinical models. This discovery centers on RORγt+ antigen-presenting cells (APCs), which interact with T cells in the intestine to establish immune tolerance. Image data from the study shows these critical cell aggregates, with RORγt+ APCs appearing in red and green and T cells in blue and red. The findings suggest that modulating this signaling pathway could open new therapeutic avenues not only for IBD but also for food allergies and other autoimmune conditions. Dr. Gregory Sonnenberg, senior author of the study and the Henry R. Erle, M.D.-Roberts Family Professor of Medicine at Weill Cornell Medicine, emphasized the paradigm-shifting nature of the discovery. “We think this is a paradigm-shifting discovery that will lead to new treatment approaches for chronic inflammatory disorders of the intestine,” he stated. Dr. Mengze Lyu served as lead and co-corresponding author on the study. The research focused on understanding how the immune system normally suppresses inappropriate chronic inflammation in the intestine by tolerating commensal gut microbes and foreign proteins from food. By examining a signal long considered essential for expanding tolerance-enforcing cells, the team found that inhibiting this signal—rather than activating it—was effective in driving tolerance through a specific cell subset. This approach represents a significant shift from conventional IBD therapies, which primarily aim to block inflammatory pathways. Instead, enhancing natural tolerance mechanisms may offer a more targeted and potentially safer strategy for managing chronic intestinal inflammation. While the study was conducted in preclinical models, the implications for human health are substantial. Current IBD treatments, including biologic agents targeting specific immune pathways, have improved outcomes for many patients but often come with risks of immunosuppression and loss of response over time. Therapies that promote immune tolerance could address these limitations by working with the body’s own regulatory systems. Further research will be needed to translate these findings into clinical applications. However, the identification of this immune tolerance switch provides a promising foundation for developing next-generation treatments that restore balance to the gut immune system rather than broadly suppressing it. As IBD continues to pose significant challenges for patients and healthcare systems, discoveries like this highlight the importance of fundamental immunology research in uncovering novel therapeutic strategies. By focusing on the mechanisms of tolerance rather than just inflammation, scientists may be able to develop more precise and effective treatments for this complex condition.
35